Merck's Calderasib Gets FDA's Breakthrough Therapy Tag for NSCLC
- Posted on June 1, 2026
- By Bing News
- 0 Views
- 1 min read
Merck's Calderasib Gets FDA's Breakthrough Therapy Tag for NSCLC
Merck MRK announced that the FDA has granted Breakthrough Therapy designation to its investigational oral specific KRAS G12C inhibitor, calderasib (MK-1084), for treating certain patients with newly diagnosed metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC). The regulatory body granted Breakthrough Therapy designation to calderasib in combination with Merck’s blockbuster PD-L1 inhibitor Keytruda for the first-line treatment of...
